Welcome to our dedicated page for Rubius Therapeutics news (Ticker: RUBY), a resource for investors and traders seeking the latest updates and insights on Rubius Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rubius Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rubius Therapeutics's position in the market.
Rubius Therapeutics (Nasdaq: RUBY) announced the dosing of the first patient in its Phase 1/2 clinical trial for RTX-224, targeting certain relapsed/refractory solid tumors. This therapy aims to stimulate a robust immune response in patients with cancers such as non-small cell lung cancer and triple-negative breast cancer. RTX-224 is designed as an off-the-shelf cellular therapy that expresses 4-1BB ligand and interleukin-12. The study will assess safety, tolerability, pharmacokinetics, and anti-tumor activity, marking a significant step forward in Rubius's therapeutic pipeline.
Rubius Therapeutics (Nasdaq: RUBY) reported significant advancements in its clinical oncology pipeline during 2021, including preclinical success in Type 1 diabetes and expected results from several clinical trials in 2022. The RTX-240 Phase 1 trial showed no dose-limiting toxicities, with further results anticipated in Q1 2022. Initial results for RTX-321 in HPV 16-positive cancers are expected in 2H 2022. The company plans to scale manufacturing capabilities to support commercial potential, emphasizing the versatility of its RED PLATFORM® in developing therapies for cancer and autoimmune diseases.
Rubius Therapeutics, a clinical-stage biopharmaceutical company, announces that Dr. Pablo J. Cagnoni, CEO, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 8:15 a.m. ET. The presentation will focus on the company's innovative Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases. A live audio webcast will be accessible through the Investors & Media section of their website, with a replay available for 30 days post-event. Rubius has been recognized as a top workplace in Massachusetts and Rhode Island.
Rubius Therapeutics has made significant advancements with its RED PLATFORM, enabling multiple therapeutic modalities targeting various immune pathways. Preclinical data showed tolerance induction in Type 1 diabetes, potentially applicable to autoimmune diseases. The RTX-240 Phase 1 trial continues to escalate doses with no dose-limiting toxicities, and initial results are expected in Q1 2022. Manufacturing capabilities have improved, allowing a fourfold increase in cell production and a 90% success rate for clinical supplies, supporting future pivotal trials and commercialization.
Rubius Therapeutics has been recognized for the second consecutive year as one of the Top Places to Work in Massachusetts and Rhode Island. The Boston Globe and Providence Business News highlighted Rubius among medium-sized employers based on employee surveys assessing various aspects of workplace culture. Rubius emphasizes core values such as integrity and inventiveness, supporting employee well-being with comprehensive benefits. The company's focus on developing Red Cell Therapeutics aims to treat cancer and autoimmune diseases.
Rubius Therapeutics (Nasdaq: RUBY) has announced a virtual investor and analyst event on December 16, 2021, focusing on its innovative RED PLATFORM® and preclinical pipeline targeting oncology and autoimmune diseases, particularly type 1 diabetes. The event will feature key presentations from the management team and Dr. Gerald T. Nepom, addressing current treatment landscapes and unmet needs in diabetes. A Q&A session will follow the discussions. Interested parties can access the live audio webcast on the company's website, with an archived replay available for 90 days.
Rubius Therapeutics (Nasdaq: RUBY), a biopharmaceutical company specializing in Red Cell Therapeutics™, has announced that its CEO, Pablo J. Cagnoni, will join a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 10:55 a.m. EST. A live audio webcast will be accessible on the company's website, with a replay available for 90 days post-event. Rubius is focused on developing innovative treatments for cancer and autoimmune diseases using its proprietary RED PLATFORM®.
Rubius Therapeutics (Nasdaq: RUBY) announced that the U.S. FDA has cleared its Investigational New Drug application for RTX-224, a novel immune costimulatory therapy targeting cancer treatment. The recent presentation at the SITC Annual Meeting showcased preclinical data demonstrating ITX-224's ability to activate multiple immune cell types, leading to significant antitumor effects in melanoma models. The company plans to begin patient dosing in Q1 2022, highlighting a critical step in advancing their Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases.
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni will deliver a corporate update during the Jefferies London Healthcare Conference on November 18-19, 2021. The presentation will focus on the company’s advancements in Red Cell Therapeutics™, aimed at treating cancer and autoimmune diseases through genetically engineered red blood cells. The recorded audio will be accessible on the company’s website starting November 18 at 8:00 a.m. ET, with an archived replay available for 90 days.
Rubius Therapeutics, Inc. (Nasdaq: RUBY) announced the FDA's clearance of its Investigational New Drug application for RTX-224, marking its third oncology candidate. Clinical results from RTX-240, a leading candidate targeting advanced solid tumors and relapsed/refractory AML, are expected by late 2021 or Q1 2022. The company reported a net loss of $49 million in Q3 2021, with R&D expenses at $38 million, reflecting a year-over-year increase. Cash reserves are at $264 million. The leadership also sees changes with Dr. Larry Turka promoted to lead research efforts.
FAQ
What is the market cap of Rubius Therapeutics (RUBY)?
